Cargando…

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

BACKGROUND: Primary systemic treatment for ovarian cancer is surgery, followed by platinum based chemotherapy. Platinum resistant cancers progress/recur in approximately 25% of cases within six months. We aimed to identify clinically useful biomarkers of platinum resistance. METHODS: A database of o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pénzváltó, Zsófia, Lánczky, András, Lénárt, Julianna, Meggyesházi, Nóra, Krenács, Tibor, Szoboszlai, Norbert, Denkert, Carsten, Pete, Imre, Győrffy, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247127/ https://www.ncbi.nlm.nih.gov/pubmed/25408231 http://dx.doi.org/10.1186/1471-2407-14-837

Ejemplares similares

Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation
por: Lánczky, András, et al.
Publicado: (2021)

Survival analysis in breast cancer using proteomic data from four independent datasets
por: Ősz, Ágnes, et al.
Publicado: (2021)

Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments
por: Munkácsy, Gyöngyi, et al.
Publicado: (2016)

A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results
por: Ligeti, Balázs, et al.
Publicado: (2015)

Correlations of Differentially Expressed Gap Junction Connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with Breast Cancer Progression and Prognosis
por: Teleki, Ivett, et al.
Publicado: (2014)

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
por: Győrffy, Balázs, et al.
Publicado: (2013)

Author Correction: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
por: Nagy, Ádám, et al.
Publicado: (2018)

Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models
por: Krenacs, Tibor, et al.
Publicado: (2020)

Parallel Evolution under Chemotherapy Pressure in 29 Breast Cancer Cell Lines Results in Dissimilar Mechanisms of Resistance
por: Tegze, Bálint, et al.
Publicado: (2012)

Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines
por: Pénzváltó, Zsófia, et al.
Publicado: (2013)

Connexin 43 Communication Channels in Follicular Dendritic Cell Development and in Follicular Lymphomas
por: Rajnai, Hajnalka, et al.
Publicado: (2015)

Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts
por: Vancsik, Tamas, et al.
Publicado: (2018)

New network topology approaches reveal differential correlation patterns in breast cancer
por: Bockmayr, Michael, et al.
Publicado: (2013)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients
por: Szász, A. Marcell, et al.
Publicado: (2016)

MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers
por: Gurbi, Bianka, et al.
Publicado: (2023)

Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting
por: Pongor, Lőrinc S., et al.
Publicado: (2020)

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan
por: Menyhárt, Otília, et al.
Publicado: (2019)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models
por: Sztupinszki, Zsófia, et al.
Publicado: (2016)

Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer
por: Győrffy, Balázs
Publicado: (2023)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

The human ABCB6 protein is the functional homologue of HMT-1 proteins mediating cadmium detoxification
por: Rakvács, Zsófia, et al.
Publicado: (2019)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin
por: Zhou, Zhiyang, et al.
Publicado: (2022)

Calcilytic NPS 2143 Reduces Amyloid Secretion and Increases sAβPPα Release from PSEN1 Mutant iPSC-Derived Neurons
por: Lo Giudice, Maria, et al.
Publicado: (2019)

Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma – a pilot study
por: Bánvölgyi, András, et al.
Publicado: (2019)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
por: Budczies, Jan, et al.
Publicado: (2012)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
por: Zhang, Yiping, et al.
Publicado: (2018)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer
por: Konstantinopoulos, Panagiotis A, et al.
Publicado: (2008)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k3sdk7lp8nbc208elltn04141r